Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
INTELLIA THERAPE RG (NQ: NTLA)
31.63 USD  +0.63 (+2.03%)
Official Closing Price  /  Updated: 5:20 PM EDT, Jul 19, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 405,774
Open 31.19
Bid (Size) 30.63 (200)
Ask (Size) 31.60 (400)
Prev. Close 31.00
Today's Range 30.18 - 31.69
52wk Range 14.53 - 35.99
Shares Outstanding 43,089,810
Dividend Yield N/A
Performance
YTD
+47.05%
+47.05%
1 Month
+9.26%
+9.26%
3 Month
+39.16%
+39.16%
6 Month
+54.29%
+54.29%
1 Year
+103.15%
+103.15%
Top News
More News
CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Announce Grant of U.S. Patent for CRISPR/Cas9 Genome Editing
CRISPR Therapeutics (NASDAQ:CRSP), Intellia Therapeutics, Inc. (NASDAQ:NTLA), and Caribou Biosciences, Inc., announced that The Regents of the University of California, the University of Vienna and... Read More
from GlobeNewswire News Releases
Stock Upgrades: Intellia Therapeutics Shows Rising Relative Strength
A Relative Strength Rating upgrade for Intellia Therapeutics shows improving technical performance. Read More
from Investor's Business Daily
More News
Read More
UPDATE 2-CRISPR gene editing can cause risky collateral DNA damage - study
category companyNews
from Reuters: Company News
UPDATE 1-CRISPR gene editing can cause risky collateral DNA damage - study
category companyNews
from Reuters: Company News
Biotech Stocks Crispr, Editas, Intellia Fall On Gene-Editing Study
from Investor's Business Daily
Yet Another CRISPR Worry: What Should Investors Do?
category EDIT , NTLA , Market News , and 1 more.
from Motley Fool
First Week of NTLA August 17th Options Trading
category Stocks
from Market News Video
Here's Why CRISPR Stocks Have Gained as Much as 169% in 2018 (So Far)
category CRSP , NTLA , Market News , and 1 more.
from Motley Fool
Intellia Confirms Crispr Risk Irrelevant To Its Program, With No Adjustments Needed
category NTLA , Market News , Thomas Barnes , and 8 more.
from Benzinga
A Deep Dive Into The Latest CRISPR Controversy: Here’s What You Should Know
category CRSP , EDIT , NTLA , and 1 more.
from Motley Fool
Editas Medicine Stock History: The Story Behind the CRISPR Gene-Editing Pioneer
category NTLA , Market News , AGN , and 2 more.
from Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X